Companies › Odyssey Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Other, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OD-07656 | – | Phase 2 | Ulcerative Colitis (UC) | Nov 2026 |
| [14C]OD-001 | – | Phase 1 | Health Volunteers | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06850727 | OD-07656 | Phase 2 | Ulcerative Colitis (UC) | Immunology | Nov 2026 |
| NCT07900607 | [14C]OD-001 | Phase 1 | Health Volunteers | Other | Dec 2026 |
Cash and short-term investments of $326m on 2026-09-30; operating cash outflow about $157m a year; runway about 25 months at that burn, to Oct 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Oruka Therapeutics Mirador Therapeutics Kymera Therapeutics Accro Bioscience (Suzhou) Shattuck Labs
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.